Landmark analysis at 3 months for patients from the 2 cohorts. Landmark analysis for patients with renal involvement who reduced or sustained their GDF-15 level <4000 pg/mL and those who had an increase to ≥4000 pg/mL or did not reduce level to <4000 pg/mL in the test cohort (A) and validation cohort (B). Figures depict time to initiation of dialysis.